This study established that in a group of patients with clinically diagnosed moderate AD, plasma samples contained elevated tau compared to NCs, whereas the levels of Aβ42 in the AD groups had either a small increase (in NTUH cohort) or an increasing trend (BSHRI cohort). The gene discussed is MAPT; the disease is Alzheimer disease.